Lobeline for Smoking Cessation
Overview
Health Services
Authors
Affiliations
Background: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking.
Objectives: The objective of this review was to assess the effects of lobeline on long term smoking cessation.
Search Strategy: We searched the Cochrane Tobacco Addiction Group trials register.
Selection Criteria: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up.
Data Collection And Analysis: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up.
Main Results: We identified no trials meeting the full inclusion criteria including long term follow-up.
Reviewer's Conclusions: There is no evidence available from long term trials that lobeline can aid smoking cessation.
Wang J, Hong M, Cheng Y, Wang X, Li D, Chen G Clin Transl Med. 2024; 14(5):e1680.
PMID: 38769668 PMC: 11106511. DOI: 10.1002/ctm2.1680.
Nicotine receptor partial agonists for smoking cessation.
Livingstone-Banks J, Fanshawe T, Thomas K, Theodoulou A, Hajizadeh A, Hartman L Cochrane Database Syst Rev. 2023; 5:CD006103.
PMID: 37142273 PMC: 10169257. DOI: 10.1002/14651858.CD006103.pub8.
From -Lobeline to -Lobeline: Study on the Pharmacodynamics and Isomerization Factors.
Xu H, Yang L, Tang M, Ye A, Tu B, Jiang Z Molecules. 2022; 27(19).
PMID: 36234790 PMC: 9573392. DOI: 10.3390/molecules27196253.
Beyond Alkaloids: Novel Bioactive Natural Products From Species.
Zheng Q, Wang Y, Zhang S Front Pharmacol. 2021; 12:638210.
PMID: 33762957 PMC: 7982472. DOI: 10.3389/fphar.2021.638210.
Nicotine receptor partial agonists for smoking cessation.
Cahill K, Lindson-Hawley N, Thomas K, Fanshawe T, Lancaster T Cochrane Database Syst Rev. 2016; (5):CD006103.
PMID: 27158893 PMC: 6464943. DOI: 10.1002/14651858.CD006103.pub7.